Peptide data sheet
CJC-1295
Performance · CJC1295 · Mod GRF 1-29
Verdict
unprovenThe unproven label reflects a real, measurable effect on hormone markers in research paired with an almost complete absence of controlled human trials on the body-composition and performance outcomes people actually want.
Quick answer
CJC-1295 is a synthetic growth-hormone-releasing-hormone (GHRH) analog commonly researched for its effect on growth-hormone and IGF-1 markers. Early studies suggest it can raise those markers, but controlled human data on real-world outcomes like fat loss or muscle is thin. It is not FDA-approved and is sold for laboratory research use only; reported side effects and gray-market supply risks are covered below.
- Class
- Growth-hormone-releasing hormone (GHRH) analog
- Half-life
- the DAC version is reported to last about 6 to 8 days; the No-DAC form (Mod GRF 1-29) is much shorter, on the order of tens of minutes (reported)
- FDA status
- Not FDA-approved. Sold as a research chemical for laboratory use only; not intended for human use.
- WADA banned?
- Yes
Which form actually works?
CJC-1295 with DAC
Unproven
The long-acting version, engineered to linger far longer than the natural hormone it mimics. People report interest in it for its convenience, but the longer action is also why some researchers flag a more sustained, less physiological signal. Controlled human outcome data remains limited.
CJC-1295 No-DAC (Mod GRF 1-29)
Unproven
The short-acting form, often discussed alongside ipamorelin because their timing is thought to pair well. It is the version people most associate with the popular stack, but that pairing is a community practice, not an outcome established in trials.